Ann Arbor, Michigan 48109

  • Barrett Esophagus

Purpose:

The overall aim of this feasibility study is to develop new technologies for improved detection of Barrett's neoplasia using the scanning fiber endoscope(SFE) multiplexed imaging system. This study will combine the use of fluorescent-labeled peptides that bind specifically to pre-cancerous mucosa in the esophagus for use as novel imaging agents to guide endoscopic biopsy or endoscopic mucosal resection (EMR). This Phase 1 study will be used to provide early evidence of efficacy for the topical application of a panel of two peptides that bind to molecular targets that are specific for esophageal dysplasia. A panel is needed because cancer in the esophagus is genetically heterogeneous. The study will look at peptide binding in subjects with known or suspected Barrett's esophagus.


Criteria:

Inclusion Criteria: - Known or suspected Barrett's esophagus - Scheduled for a clinically-indicated upper endoscopy - Medically cleared for the procedure - Willing and able to sign informed consent Exclusion Criteria: - Known allergy or negative reaction to the near infrared fluorophores Cy5, li-cor IRDye800CW, or derivatives - One active chemotherapy or radiation treatment - Pregnant or trying to conceive


NCT ID:

NCT03589443


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Ann Arbor, Michigan 48109
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.